KLK3 and posterior cortical atrophy: It was approved by the FDA in 1996 specifically for biopsy-proven PCa with high risk for pelvic lymph node metastases and for detecting recurrence in patients with rising prostate-specific antigen (PSA) levels following prostatectomy.